An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

NCT02049138 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

493

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Upadacitinib
BIOLOGICAL: Pneumococcal 13-valent conjugate vaccine (PCV-13)

Sponsor

AbbVie